Figure 2

Inhibition of tumor cell proliferation in vitro by hPUMA and cisplatin. The MTT assay was performed as described in Materials and Methods. (A) The treatment of cisplatin at indicated concentrations and periods reduced A2780s cell viability, showing that the dose of IC₅₀ ranged from 5 to 10 µg/mL. (B) The treatment of hPUMA plus cisplatin reduced A2780s cell viability more significantly than the treatment of hPUMA alone or cisplatin alone. Significant differences compared with the control group: 24 h, **P ≤ 0.001; 48 h, ^##P ≤ 0.001. (C) The treatment of cisplatin alone had little effect on survival of SKOV3 cells, and the combination of hPUMA plus cisplatin reduced SKOV3 cell viability more significantly than the treatment of hPUMA alone or cisplatin alone. Significant differences compared with the control group: 24 h, **P ≤ 0.001; 48 h, ^##P ≤ 0.001). Percentage of survival was calculated. Results are shown as means ± SD of six wells and triplicate experiments. In each experiment, the medium-only treatment (untreated) indicates 100% cell viability.